{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T06:03:57Z","timestamp":1780380237376,"version":"3.54.1"},"reference-count":101,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clml.2022.01.009","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T18:54:12Z","timestamp":1642618452000},"page":"442-459","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-5166","authenticated-orcid":false,"given":"Fabio","family":"Efficace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Caocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajshekhar","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.01.009_bib0001","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.V73.4.865.865","article-title":"Plasma cell myeloma\u2013new biological insights and advances in therapy","volume":"73","author":"Barlogie","year":"1989","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.01.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.clml.2022.01.009_bib0003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood-2020-134847","article-title":"Updated analysis of daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM): the phase 3 Maia study","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.009_bib0004","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.009_bib0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0006","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/JCO.2003.12.121","article-title":"Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials\u2013does HRQOL evaluation in prostate cancer research inform clinical decision making?","volume":"21","author":"Efficace","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0007","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1470-2045(18)30097-4","article-title":"Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada","volume":"19","author":"Kluetz","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0008","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","article-title":"Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?","volume":"130","author":"Efficace","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.009_bib0009","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0011","doi-asserted-by":"crossref","first-page":"e892","DOI":"10.1016\/S2352-3026(20)30292-1","article-title":"Quality of patient-reported outcome reporting in randomised controlled trials of haematological malignancies according to international quality standards: a systematic review","volume":"7","author":"Chakraborty","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0012","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","article-title":"Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma","volume":"87","author":"Kvam","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0013","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/cancers13112639","article-title":"CART-cell therapy: recent advances and new evidence in multiple myeloma","volume":"13","author":"Martino","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2022.01.009_bib0014","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/bmjspcare-2019-001902","article-title":"Inclusion of older patients with cancer in randomised controlled trials with patient-reported outcomes: a systematic review","volume":"9","author":"Sparano","year":"2019","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.clml.2022.01.009_bib0015","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jnci\/djz038","article-title":"Systematic evaluation of patient-reported outcome protocol content and reporting in cancer trials","volume":"111","author":"Kyte","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clml.2022.01.009_bib0016","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2022.01.009_bib0017","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.clml.2022.01.009_bib0018","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s11136-012-0252-1","article-title":"Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards","volume":"22","author":"Brundage","year":"2013","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2022.01.009_bib0019","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2022.01.009_bib0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11136-010-9793-3","article-title":"Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers","volume":"20","author":"Brundage","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2022.01.009_bib0021","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1200\/JCO.18.01006","article-title":"Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma","volume":"37","author":"Ahmedzai","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0022","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.009_bib0023","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.01.009_bib0024","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.009_bib0025","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s00277-018-3469-4","article-title":"Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study","volume":"97","author":"Cella","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0026","doi-asserted-by":"crossref","first-page":"e340","DOI":"10.1016\/S2352-3026(16)30049-7","article-title":"The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT\/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial","volume":"3","author":"Cook","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0027","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(14)70245-1","volume":"15","author":"Cook","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0028","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.009_bib0029","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.01.009_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","article-title":"All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"106","author":"Dimopoulos","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2022.01.009_bib0031","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0032","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.009_bib0033","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3109\/10428194.2013.847933","article-title":"Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged \u2265 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial","volume":"55","author":"Dimopoulos","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.01.009_bib0034","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.3324\/haematol.2018.194282","article-title":"Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX","volume":"103","author":"Dimopoulos","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.009_bib0035","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0036","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.009_bib0037","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","article-title":"Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"133","author":"Facon","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.009_bib0038","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40164-018-0110-0","article-title":"A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma","volume":"7","author":"Gregersen","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0039","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.01.009_bib0040","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/bjh.17321","article-title":"Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial","volume":"193","author":"Hungria","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0041","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0042","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25134","article-title":"Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma","author":"Leleu","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0043","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.009_bib0044","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-019-0181-0","article-title":"Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed\/refractory multiple myeloma","volume":"9","author":"Ludwig","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.01.009_bib0046","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0047","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.01.009_bib0048","doi-asserted-by":"crossref","unstructured":"Moreau P., Kumar S., Boccia R., Convenience, satisfaction, health-related quality of life of once-weekly 70 mg\/m(2) vs. twice-weekly 27 mg\/m(2) carfilzomib (randomized A.R.R.O.W. study). Leukemia. 2019;33:2934-2946.","DOI":"10.1038\/s41375-019-0480-2"},{"key":"10.1016\/j.clml.2022.01.009_bib0049","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.009_bib0050","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","article-title":"Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study","volume":"19","author":"Moreau","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0051","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/ejh.13175","article-title":"Clarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients","volume":"102","author":"Nielsen","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0052","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3324\/haematol.2019.222299","article-title":"Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study","volume":"105","author":"Nielsen","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.009_bib0053","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0054","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0055","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.009_bib0056","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.009_bib0057","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1200\/JCO.20.01370","article-title":"Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: findings from the phase III MAIA trial","volume":"39","author":"Perrot","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0058","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjh.17435","article-title":"Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial","volume":"194","author":"Plesner","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0059","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.14483","article-title":"Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma","volume":"176","author":"Raje","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0060","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","article-title":"Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.009_bib0061","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0062","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjh.15248","article-title":"Patient-reported outcomes of multiple myeloma patients treated with panobinostat after \u22652 lines of therapy based on the international phase 3, randomized, double-blind, placebo-controlled PANORAMA-1 trial","volume":"181","author":"Richardson","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0063","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1080\/10428194.2020.1719091","article-title":"Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"61","author":"Roussel","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.01.009_bib0064","doi-asserted-by":"crossref","first-page":"e874","DOI":"10.1016\/S2352-3026(20)30356-2","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial","volume":"7","author":"Roussel","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0065","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15459","article-title":"Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the medical research council myeloma IX randomised study","volume":"182","author":"Royle","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0066","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1182\/blood-2013-12-546374","article-title":"Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma","volume":"123","author":"San-Miguel","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.009_bib0067","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0068","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/ejh.13379","article-title":"Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: the TOURMALINE-MM3 trial","volume":"104","author":"Schjesvold","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0069","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3324\/haematol.2014.112557","article-title":"Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"100","author":"Song","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.009_bib0070","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.01.009_bib0071","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","article-title":"Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma","volume":"34","author":"Stewart","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0072","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1182\/blood-2014-12-613927","article-title":"Melphalan, prednisone, and thalidomide vs melphalan, prednisone, and lenalidomide (ECOG E1A06) in untreated multiple myeloma","volume":"126","author":"Stewart","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.009_bib0073","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.01.009_bib0074","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1080\/10428194.2017.1334125","article-title":"Long-term health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma receiving lenalidomide and dexamethasone","volume":"59","author":"Vogl","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.01.009_bib0075","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1080\/10428194.2020.1747066","article-title":"Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma","volume":"61","author":"Weisel","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.01.009_bib0076","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","article-title":"Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed\/refractory patients with multiple myeloma enrolled in the MM-003 randomized phase III trial","volume":"15","author":"Weisel","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.01.009_bib0077","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.01.009_bib0078","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1200\/JCO.2016.66.7295","article-title":"Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial","volume":"34","author":"Hulin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0079","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0080","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0081","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0082","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2022.01.009_bib0083","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.01.009_bib0084","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the european organisation for the research and treatment of cancer quality of life questionnaire core 30","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2022.01.009_bib0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European organisation for the research and treatment of cancer quality of life questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0086","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0087","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.01.009_bib0088","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomized clinical trial in the era of precision oncology","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0089","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jval.2020.11.004","article-title":"Past and current practice of patient-reported outcome measurement in randomized cancer clinical trials: a systematic review","volume":"24","author":"Giesinger","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2022.01.009_bib0090","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1007\/s00520-018-4137-x","article-title":"Patient-reported outcomes in relapsed\/refractory multiple myeloma: a systematic review","volume":"26","author":"Sparano","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2022.01.009_bib0091","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-021-00543-y","article-title":"Review of patient-reported outcomes in multiple myeloma registrational trials: highlighting areas for improvement","volume":"11","author":"Fernandes","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2022.01.009_bib0092","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s11136-019-02392-6","article-title":"How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review","volume":"29","author":"LeBlanc","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2022.01.009_bib0093","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1046\/j.0902-4441.2003.00195.x","article-title":"Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences","volume":"72","author":"Gulbrandsen","year":"2004","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2022.01.009_bib0094","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdl494","article-title":"Has the quality of health-related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap with clinical decision making","volume":"18","author":"Efficace","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0095","unstructured":"US Department of Health and Human Services Food and Drug Administration. Guidance for industry: E9(R1) statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials. Accessed from: https:\/\/www.fda.gov\/media\/148473\/download. Accessed at: May 8, 2021"},{"key":"10.1016\/j.clml.2022.01.009_bib0096","unstructured":"European Medicine Agency. ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Step 5. 2021. Accessed from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf. Accessed at: May 8, 2021"},{"key":"10.1016\/j.clml.2022.01.009_bib0097","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jclinepi.2020.06.016","article-title":"Time to health-related quality of life improvement analysis was developed to enhance evaluation of modern anticancer therapies","volume":"127","author":"Cottone","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clml.2022.01.009_bib0098","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.01.009_bib0099","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11136-019-02304-8","article-title":"Strategies to improve patient-reported outcome completion rates in longitudinal studies","volume":"29","author":"Nielsen","year":"2020","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clml.2022.01.009_bib0100","unstructured":"Friends of Cancer Research. Broadening the definition of tolerability in cancer clinical trials to better measure the patient experience. 2018. Accessed from: https:\/\/www.focr.org\/sites\/default\/files\/Comparative%20Tolerability%20Whitepaper_FINAL.pdf. Accessed at: August 31, 2021."},{"key":"10.1016\/j.clml.2022.01.009_bib0101","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","article-title":"Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany","volume":"21","author":"Engelhardt","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022000143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T16:35:16Z","timestamp":1726504516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022000143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":101,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S2152265022000143"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Reported Outcomes in Randomized Controlled Trials of Patients with Multiple Myeloma: A Systematic Literature Review of Studies Published Between 2014 and 2021","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}